What Гордокс treats: Main Uses and Benefits

Гордокс (Aprotinin) is a specialized medication used only in the acute setting of major surgery to manage the complex challenge of blood loss, and provides supportive relief when symptoms of hemorrhage risk are heightened. It is applied across therapeutic domains involving heightened physiological stress, such as isolated Coronary Artery Bypass Graft (CABG) surgery and other complex cardiac procedures.

Therapeutic application is indicated for managing the symptomatic domain of perioperative blood loss and the reliance on blood product transfusions in adult patients. The medication helps address specific symptomatic clusters: the anticipation of severe surgical bleeding and the subsequent high requirement for allogeneic (donor) blood transfusions. The supportive role of the medication helps patients cope more steadily with the immediate recovery phase.

Quick Fact: Relief for Surgical Blood Loss

Symptom Domain	Primary Benefit	Clinical Context
Excessive Bleeding Risk	Supports the management of blood loss	Procedures involving cardiopulmonary bypass
Transfusion Needs	May assist with managing the reliance on donor blood products	High-risk adult surgical patients

Official Eligibility and Contraindications for Гордокс (Aprotinin)

The use of Гордокс (Aprotinin) is strictly governed by regulatory bodies due to significant safety concerns, limiting its use to a specific patient population under highly controlled conditions.

Populations Who Must Not Use Гордокс (Contraindications):

Category	Regulatory Status
Immune Status	Known hypersensitivity to Aprotinin or any excipient, a positive test for Aprotinin-specific IgG antibodies, or suspected previous exposure (including in fibrin sealants) within the last 12 months.

Eligible Population (Restricted Use):

Use is allowed only in adult patients who are at high risk of major blood loss and are undergoing isolated Coronary Artery Bypass Graft (CABG) surgery. Use for CABG combined with any other cardiovascular surgery is not established and is restricted.

Special Population Restrictions:

• Age-Related: Use in children and adolescents under 18 years of age is not established due to a lack of sufficient safety and efficacy data, and is generally prohibited. Use in older adults is generally permitted without dose adjustment.
• Organ Function: Patients with pre-existing renal dysfunction require careful consideration of the risks versus benefits because the drug may potentially trigger or worsen kidney impairment.
• Pregnancy/Lactation: Use during pregnancy is generally advised only when the expected benefit outweighs the potential risk to the fetus. Use during lactation is often contraindicated or not recommended.

---

Connection to the Overall Eligibility Profile

Official regulatory documents define eligibility for Гордокс through strict contraindications concerning prior drug exposure and immune status to mitigate the risk of severe allergic reactions. The drug is authorized only for a narrow, high-risk adult surgical cohort, making its use prohibited or not established across all pediatric populations and conditional in patients with pre-existing renal impairment.

Interactions with other medicines and products

Official regulatory documents describe several clinically significant interactions for Aprotinin ( Гордокс), primarily based on pharmacodynamic effects and physical compatibility constraints rather than CYP enzyme metabolism.

---

Pharmacodynamic Interactions

Interacting Product Category	Interaction Statement
Fibrinolytic Agents (e.g., Streptokinase, Urokinase)	Aprotinin inhibits the activity of these agents in a dose-dependent manner.
ACE Inhibitors (e.g., Captopril)	Aprotinin has been documented to block or counteract the acute hypotensive effect of these medicines.
Nephrotoxic Drugs (e.g., Aminoglycosides)	Caution is advised regarding the potential for enhanced kidney risk, especially in patients with pre-existing renal impairment.

---

Procedural and Compatibility Constraints

Physical Incompatibility: Aprotinin is incompatible with certain solutions and must not be added to mixed infusions containing specific IV products, including some antibiotics and nutrient solutions (e.g., amino acid or fat emulsions).

Timing and Admixture: When administered with Heparin, the agents must be added separately and adequately diluted during the preparation of the pump prime solution to avoid physical incompatibility.

Laboratory Interference: Aprotinin can prolong the Activated Clotting Time ( ACT), particularly when measured using the celite surface activation method, which must be considered during monitoring.

Гордокс is the brand name for aprotinin, a polypeptide compound that functions as a broad-spectrum serine protease inhibitor. Its core mechanism involves the direct and reversible binding to, and subsequent inactivation of, several key proteolytic enzymes that participate in various acute physiological responses.

The drug's action centers on the inhibition of serine proteases, notably plasmin, kallikrein, and trypsin. By suppressing these enzymes, Гордокс modifies molecular steps within critical systems. Inhibition of kallikrein regulates processes within the kallikrein-kinin system, influencing the synthesis of potent vasoactive and inflammatory mediators. This action restricts mediator synthesis, thereby modulating pathway activity. Concurrently, the inhibition of plasmin targets a core enzyme of the fibrinolytic pathway. This specific enzymatic modification influences systemic enzymatic balance, leading to the modulation of subsequent fibrinolytic activity within targeted pathways. This overall pharmacodynamic effect results in the adjustment of overactive or dysregulated proteolytic processes at a systemic level.

How to Use Гордокс

Гордокс (Aprotinin) is a specialized, prescription-only medication administered exclusively in the hospital setting by specialists. Its use is limited to a single, acute course during major surgical procedures, following a highly specific, multi-step established protocol.

Official Administration and Dosing

The only approved route of administration is Intravenous (IV). The standardized use involves a sequential, weight-independent dosing regimen that is tied directly to the timeline of the operation. This protocol is designed to ensure precise delivery throughout the procedure.

Dosing Component	Official Regimen (Example)
Route of Administration	Intravenous (IV) infusion/injection only.
Loading Dose	1 million to 2 million KIU, administered slowly over 20–30 minutes.
Pump Prime Dose	1 million to 2 million KIU added to the heart-lung machine volume.
Maintenance Infusion	250,000 to 500,000 KIU per hour, continued until the end of the operation.

Administration Requirements

Official instructions mandate specific procedural steps for safe and proper administration:

• IV Access: The drug must be infused using a central venous catheter.
• Rate: Administration of the loading dose must be performed slowly, at a maximum rate of 5 to 10 ml/minute.
• Preparation: When adding the drug to the heart-lung machine prime, Aprotinin and Heparin must be introduced separately during fluid recirculation to ensure adequate dilution and prevent physical incompatibility.

Population-Specific Use

There are no special dose recommendations for older adults or for patients with renal or hepatic impairment. Furthermore, the safety and effectiveness of Aprotinin have not been established for use in pediatric patients (under 18 years of age).

Research Evidence / Overview of Studies for Гордокс (Aprotinin)

---

Evidence for Use in Preventing Blood Loss During Cardiac Surgery

This section will summarize the available evidence from controlled studies, primarily randomized trials, that have investigated the use of this product (Aprotinin) to describe research evaluating intraoperative blood loss and the need for blood transfusions in adult patients undergoing isolated coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB).

Studies evaluating the use of this product were conducted in research scenarios involving open-heart procedures. Researchers examined whether research observed differences in the amount of blood lost and the number of red blood cell transfusions required between groups compared to patients who received a placebo. These trials included adult patients undergoing CABG surgery.

The findings describe patterns observed in these studies where the groups that received the product generally reported different measured amounts of blood loss and transfusion requirements compared to the control groups during and immediately following the operation. However, the certainty regarding all aspects of this use remains low. Results apply only to the populations studied—specifically, adults undergoing isolated CABG with CPB.

---

Long-term Studies and Follow-up

Research exploring short-term changes in blood loss and transfusion requirements typically focused on the time period immediately surrounding the surgery. This means that long-term outcomes are not fully established.

Follow-up durations were limited in the primary trials conducted. Therefore, there is limited information for long-term outcomes, such as how the product may be associated with events happening months or years after the surgery. For example, research describes patterns observed in the studies related to acute kidney injury (a temporary physiological imbalance) after surgery, but information characterizing outcomes related to long-term kidney function is limited.

---

Evidence in Special Populations

The primary body of evidence examined adult patients. As a result, data for certain groups remain insufficient. For pediatric patients (children and adolescents) undergoing cardiac procedures, comparative evidence is lacking, and the results apply only to the adult populations studied. Therefore, research does not determine whether an individual in a younger population will report similar outcomes.

Likewise, for patients with pre-existing renal impairment, while some studies measured outcomes related to physiological strain or stress (such as renal markers), the sample sizes were modest, and data characterizing the use of the product in patients with significant renal impairment are limited.

Key Studies & References

1. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials
2. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis
3. Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a systematic review and meta-analysis of observational studies

Common questions about Гордокс (FAQ)

Q: Can Гордокс cause a fever or chills?

Fever and chills have been reported as documented side effects associated with the use of this medicine, according to official product information.

Q: Is Гордокс safe to use if I have kidney problems?

Patients with pre-existing kidney impairment require extreme caution when this product is used. Regulatory documents note an increased risk of worsening the condition, as acute kidney injury is a potential side effect.

Q: Can people with a history of allergies take Гордокс?

A known hypersensitivity or specific allergy to the active substance, Aprotinin, or any excipients is considered a contraindication, which restricts its use. The risk of a severe allergic reaction is also significantly higher in patients who have previously received the product.

Q: Is it normal to feel dizzy or lightheaded after getting Гордокс?

Dizziness and lightheadedness have been reported as documented side effects of the product, according to official safety information. Patients are closely monitored by the medical team during administration for any immediate effects.

Q: How long does the effect of one dose of Гордокс last in the body?

The product is administered continuously throughout the operation. After the infusion stops, the product enters a terminal elimination phase. Pharmacokinetic studies show the elimination half-life is approximately 10 hours.

Q: What should I do if I think I'm having a side effect from Гордокс?

Because this medicine is only administered in a hospital setting, patients are continuously monitored by medical professionals for any adverse effects. The hospital protocol ensures that equipment and medication for emergency treatment are readily available.

Q: Can Гордокс be used in children or only adults?

The product is approved for use only in adult patients. Its use is not established in patients under 18 years of age due to a lack of sufficient safety and efficacy data.

Q: Does Гордокс interact with blood thinners?

Regulatory documents indicate interactions with fibrinolytic agents, which are drugs used to dissolve blood clots. Official warnings note that full and adequate anticoagulation with Heparin (a common blood thinner) must be maintained throughout the procedure.

Q: Are there different forms of Гордокс (e.g., tablet vs. injection)?

According to official product documentation, Гордокс is only supplied as a sterile solution intended for intravenous injection or infusion. The product is not available in a tablet or oral form.

Q: Does food or drink affect how Гордокс works?

Regulatory information indicates that the usage of this product is not dependent on food timings. Given that the medicine is administered directly into a vein in a hospital setting, its absorption and efficacy are not typically affected by food or drink.

Q: Can I take vitamins or supplements while on a course of Гордокс?

The healthcare team must be aware of all medicines, including over-the-counter drugs, vitamins, and herbal products, that a patient is taking. Potential interactions must be considered before administration of this medicine.

Q: Why do they sometimes use Гордокс during or after surgery?

The approved use for this product is to reduce blood loss and the need for blood transfusions. It is administered to adult patients during high-risk cardiac surgery, specifically isolated coronary artery bypass grafting (CABG).

Q: Is Гордокс used in emergency situations?

Its approved use is for high-risk surgical scenarios, such as isolated coronary artery bypass grafting (CABG), specifically to reduce blood loss and the need for transfusions.

Q: Is it okay to drink alcohol a day after receiving Гордокс?

Information on the interaction between this product and alcohol is currently unknown. Due to the lack of specific data, any consumption should be discussed with the attending healthcare provider.

Q: Why is the infusion time for Гордокс so slow sometimes?

Official administration instructions specify a slow infusion rate to minimize the risk of adverse events, such as allergic reactions or hypotensive reactions (a sudden drop in blood pressure).

Official Storage and Disposal Requirements

The storage and disposal of Гордокс (Aprotinin) injection solution are governed by specific regulatory conditions to maintain product integrity and ensure safety.

Requirement Domain	Official Condition
Temperature Restriction	Must be stored below 25 C (77°F); avoid freezing the solution.
Container & Protection	Store in the original package to protect from light; visually inspect the solution for any change or particulate matter prior to use.
Stability & Handling	The product is a single-use vial; any residual solution must not be kept for later use. Incompatibility with certain substances like heparin or corticosteroids must be considered when mixing.
Disposal	Must be kept out of the sight and reach of children. Unused product and waste material must be disposed of in accordance with local regulatory requirements.

These instructions define how the product must be protected from environmental factors and handled post-use, adhering strictly to government-approved labeling.